Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Ponatinib in Newly Diagnosed CML
Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response.
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
N C P Cross,1,2,* H E White,1,2 D Colomer,3 H Ehrencrona,4 L Foroni,5 E Gottardi,6
Jun Imagawa, MD, Hideo Tanaka, MD, Masaya Okada, MD, Hirohisa Nakamae, MD, Prof Masayuki Hino, MD, Kazunori Murai, MD, Prof
M Talpaz1, R Hehlmann2, A Quintás-Cardama3, J Mercer1 and J Cortes3
Rousselot et al1 recently reported on the According to Stop Imatinib (A-STIM) study evaluating the persistence of major molecular response (MMR) in patients with chronic-phase chronic myeloid leukemia (CP CML) who had discontinued imatinib after prolonged deep molecular remission. They found that 61% of the patients were still in MMR and were treatment free after 36 months, whereas those who lost MMR and restarted tyrosine kinase inhibitor (TKI) therapy all regained MMR. They concluded that loss of MMR is a safe criterion for restarting therapy after TKI discontinuation.